Codexis, Inc. (NASDAQ:CDXS)’s share price hit a new 52-week high on Thursday . The stock traded as high as $19.25 and last traded at $18.95, with a volume of 6725 shares trading hands. The stock had previously closed at $18.90.

CDXS has been the subject of several recent research reports. Zacks Investment Research upgraded Codexis from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research report on Thursday, August 16th. BidaskClub cut Codexis from a “buy” rating to a “hold” rating in a research report on Thursday, July 26th. Cowen initiated coverage on Codexis in a research report on Tuesday, June 19th. They issued an “outperform” rating and a $18.00 price target for the company. Finally, Craig Hallum lifted their price target on Codexis from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, September 5th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Codexis presently has a consensus rating of “Buy” and an average price target of $15.50.

Codexis (NASDAQ:CDXS) last posted its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.07) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. Codexis had a negative return on equity of 61.93% and a negative net margin of 29.83%. The business had revenue of $13.54 million during the quarter, compared to analysts’ expectations of $11.87 million. equities analysts expect that Codexis, Inc. will post -0.2 EPS for the current fiscal year.

In related news, Director Patrick Y. Yang sold 150,340 shares of the business’s stock in a transaction dated Thursday, August 16th. The stock was sold at an average price of $14.45, for a total transaction of $2,172,413.00. Following the completion of the transaction, the director now directly owns 120,896 shares in the company, valued at $1,746,947.20. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP James Lalonde sold 30,296 shares of the business’s stock in a transaction dated Wednesday, September 5th. The stock was sold at an average price of $17.24, for a total value of $522,303.04. Following the transaction, the senior vice president now owns 177,151 shares of the company’s stock, valued at $3,054,083.24. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 358,836 shares of company stock valued at $5,464,028. 11.40% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of CDXS. BlackRock Inc. grew its position in Codexis by 27.3% during the second quarter. BlackRock Inc. now owns 3,402,575 shares of the biotechnology company’s stock worth $48,996,000 after buying an additional 729,552 shares in the last quarter. Lord Abbett & CO. LLC purchased a new position in Codexis during the first quarter worth about $7,544,000. FMR LLC purchased a new position in Codexis during the second quarter worth about $7,452,000. Baillie Gifford & Co. grew its position in Codexis by 25.0% during the first quarter. Baillie Gifford & Co. now owns 2,302,979 shares of the biotechnology company’s stock worth $25,332,000 after buying an additional 460,578 shares in the last quarter. Finally, Castleark Management LLC purchased a new position in Codexis during the second quarter worth about $6,239,000. Institutional investors and hedge funds own 77.35% of the company’s stock.

Codexis Company Profile (NASDAQ:CDXS)

Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.

See Also: Relative Strength Index

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.